REMARKS

Status of the Claims

Claims 1, 2, 4-8, 12-14 and 17-19 are pending in this application. Claims 3, 10, 11, 15 and 16 have been canceled. No claims have been added. The claims have been amended to particularly and distinctly recite the subject matter of the invention. No new matter has been added by the above claim amendments.

Objection to the Specification

The Examiner objects to the specification for misspelling carboxy. The Examiner also objects to the specification for reference to claim 7. Applicants amend the specification to correct the misspelling and to delete reference to claim 7 and insert the original text of claim 7 being referenced. No new matter has been introduced by these specification amendments.

Restriction Requirement

The Examiner partially maintains the Restriction Requirement and has made it final. The Examiner was not convinced by the arguments to rejoin claims 10, 11 and 15. As such, Applicants cancel withdrawn claims 10, 11 and 15.

Rejections under 35 USC 112, second paragraph

The Examiner rejects claims 1-8, 12-14 and 16-19 as indefinite for the reasons set forth at pages 3-7 of the Office Action. Applicants traverse the rejection and respectfully request the withdrawal thereof.

Applicants amend the claims as described herein to overcome the indefiniteness issues. Claim 1 has been amended to delete the two objectionable phrases. Claim 3 has been canceled; thus, the rejection of claim 3 is moot. Claim 4 has been amended to recite that the aryl is not substituted. Claim 4 has also been amended to delete the term "fragments". Claim 7 has been amended to delete reference to the site of substitution. Claim 7 has also been amended to give antecedent basis to the hydroxyl groups. Claim 8 has been amended to delete "fragment(s)". Claim 8 has been amended to recite that said substituents may have functional groups, which are protected. Claim 8 has been amended to delete reference to derivatives of the thiol, amino or carboxy groups. Reference to the placement of substituents has also been deleted. Thus no antecedent basis problems exist. Claim 12 has been amended to define the protected aminooxy. Claim 12 has also been amended to delete the term "derivatives". Claim 16 has been canceled; thus, all rejections on claim 16 are moot. Claim 17 has been amended to correct recitation of $-SO_2$ - and to delete the term "fragments" and reference to an optionally substituted aryl. Claim 18 has been amended to delete reference to derivatives. Lastly, Claim 19 has been amended to correctly recite -OP(O)(OH)O-. As such, Applicants submit that all indefiniteness issues have been overcome and the rejections should be withdrawn.

Conclusion

As Applicants have addressed and overcome all rejections in the Office Action, Applicants respectfully request that the rejections be withdrawn and that the claims be allowed.

Should there be any outstanding matters that need to be resolved in the present application, the Examiner is respectfully requested to contact Kecia Reynolds (Reg. No. 47,021) at the telephone number of the undersigned below, to conduct an interview in an effort to expedite prosecution in connection with the present application.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 02-2448 for any additional fees required under 37 C.F.R. §§ 1.16 or 1.17; particularly, extension of time fees.

Respectfully submitted,

BIRCH, STEWART, KOLASCH & BIRCH, LLP

By N n d #32,991

P.O. Box 747
Falls Church, VA 22040-0747

(703) 205-8000

ADM/KJR:bmp 0933-0160P

Attachment(s)